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The use of structured treatment interruption (STI) in human immunodeficiency virus (HIV)–infected subjects
is currently being studied as an alternative therapeutic strategy for HIV-1. The potential risk for selection of
drug-resistant HIV-1 variants during STI is unknown and remains a concern. Therefore, the emergence of
drug resistance in sequential plasma samples obtained from 28 subjects with chronic HIV infection was studied.
They underwent 4 cycles of 2-week STI, followed by 8-week retreatment with highly active antiretroviral
therapy identical to that used before STI, and they had never failed treatment before undergoing STI. At week
40, treatment was stopped for a longer period. Minor populations of drug-resistant variants were detected by
quantitative real-time polymerase chain reaction, by use of allele-discriminating oligonucleotides for 2 key
resistance mutations: L90M (protease) and M184V (reverse transcriptase). The approximate discriminative
power was 0.1%. In 14 of 25 and in 3 of 25 subjects, the M184V and the L90M mutations, respectively, were
detected as minor populations, at different times during STI. Overall, these results indicate that, in subjects
undergoing multiple STIs, HIV-1 variants carrying drug-resistance mutations can emerge during periods of
increased HIV-1 replication.
Highly active antiretroviral therapy (HAART) has re-
duced the morbidity and mortality of subjects infected
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with human immunodeficiency virus type 1 (HIV-1)
[1, 2]. However, the existence of a long-lived reservoir
of latently infected CD4+ T lymphocytes makes it un-
likely that HIV-1 can be eradicated by currently avail-
able antiretroviral drugs [3–7]. Adverse effects and
long-term toxicity, associated with prolonged use of
these drugs, has become a critical issue when consid-
ering the beneficial effects of HAART [8, 9].
Structured treatment interruption (STI) is an alter-
native therapeutic strategy for HIV-1 that is currently
under investigation. STI is used as a means of boosting
HIV-1–specific immune responses, while, at the same
time, reducing the adverse effects, toxicity, and cost
associated with HAART. Encouraging results from the
use of STI in subjects with acute HIV-1 infection, the
majority of whom controlled viral replication after ces-
sation of treatment, have been reported [10]. The clin-
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ical benefits of STI in subjects with chronic HIV-1 infection
remain unclear [11–13]. The largest STI trial undertaken thus
far, the Swiss-Spanish Intermittent Treatment Trial (SSITT),
enrolled 133 subjects with chronic HIV-1 infection who un-
derwent STI after successful HAART. The results of that trial
did not show a relationship between control of HIV-1 viremia
and induction of virus-specific cytotoxic T lymphocytes [14–
16]. However, SSITT demonstrated that STI is safe in subjects
with chronic HIV-1 infection. The risk of selecting drug-resis-
tant HIV-1 variants during STI is unknown and remains a
concern [17]. A recent report demonstrates selection of drug-
resistant viruses in the context of STI: 2 of 12 subjects with
chronic HIV-1 infection developed the M184V mutation, which
is associated with reduced susceptibility to lamivudine [18].
Genotypic mutations associated with drug resistance are gen-
erally detected by direct sequencing or hybridization to allele-
specific oligonucleotides. One drawback to these techniques is
their inability to detect and quantify minor (!20%) populations
of either the wild-type or mutant variants. This is mainly due
to the failure of polymerase chain reaction (PCR) primers to
discriminate, and subsequently to amplify, variants with a low
molar ratio [19, 20]. In a previous study, we reported a new
method for differential amplification of simian immunodefi-
ciency virus species that is based on real-time PCR using mo-
lecular beacons and selective oligonucleotides [21]. Subse-
quently, other groups have reported similar assays for the
selective quantification of resistant HIV-1 viral sequences [22].
In the present study, this technique was modified to detect 2
key HIV-1 drug-resistance mutations, L90M (protease) and
M184V (reverse transcriptase [RT]). This assay allows simul-
taneous detection of both the wild-type and drug-resistant var-
iants in the same sample, enabling direct quantification and
analysis of changes in each virus population.
To evaluate the development of minor drug-resistant HIV-
1 variants, we used this assay to assess subjects with chronic
HIV-1 infection during STI. Our results indicate the presence
of minor populations of HIV-1 with L90M and M184V mu-
tations in subjects undergoing STI.
SUBJECTS, MATERIALS, AND METHODS
Study design and subjects. Of the 29 subjects enrolled from
the Zurich cohort of the SSITT [14], 28 participated in the
present study. Of those, 15 participated in an extended protocol
with frequent blood sampling [16]. All subjects also participated
in the Swiss HIV Cohort Study.
To be eligible for the SSITT, subjects had to be receiving their
first combination antiretroviral therapy (ART) with 2 or 3 drugs
(excluding nonnucleoside RT inhibitors) for 16 months and
never have experienced therapy failure. Subjects who had re-
ceived previous nonsuppressive treatment with 1 or 2 nucleo-
side RT inhibitors were excluded. Plasma viremia had to be
!50 HIV-1 RNA copies/mL for at least 6 months, and CD4+
T cell counts had to be 1300 cells/mL. The baseline charac-
teristics of the study subjects are summarized in table 1. The
trial consisted of 4 cycles, each consisting of a 2-week treatment
interruption followed by resumed treatment for 8–10 weeks.
Subjects whose plasma viremia did not decrease to values of
!50 HIV-1 RNA copies/mL of plasma during periods of re-
sumed treatment were excluded from the study. After 4 STI
cycles (week 40), treatment was stopped for at least 3 months,
unless symptoms of acute HIV-1 infection occurred, CD4+ T
cell counts decreased to !300 cells/mL, or virus load exceeded
the following predetermined values: 3 consecutive measure-
ments of 150,000, 2 of 1100,000, or 1 of 1500,000 HIV-1 RNA
copies/mL of plasma. At week 52, treatment was resumed as
described elsewhere [14, 16]. The SSITT was approved by the
Ethics Committee of the University Hospital Zurich, and writ-
ten, informed consent was obtained from each subject.
Blood sampling and HIV-1 quantification. Blood samples
were obtained on days 0, 4, 8, 14, 18, 22, 24, 28, 35, 42, 56,
63, and 70 of each cycle, for the extended protocol, and on
days 0, 14, and 63 of each cycle, for the basic SSITT protocol.
From week 40 to 52, blood was drawn weekly from all subjects.
Plasma HIV-1 RNA was quantified by use of an Amplicor HIV-
1 Monitor test (version 1.5; Roche Diagnostics) with ultrasen-
sitive modifications, resulting in a level of detection of 50
HIV-1 RNA copies/mL of plasma [23, 24].
HIV-1 RNA from subjects’ plasma. Plasma samples col-
lected from blood in EDTA anticoagulant were centrifuged at
2000 g for 5 min, to pellet cell debris. Particle-associated HIV-
1 RNA was purified from cell-free plasma (250–500 mL) by use
of a QIAamp Viral RNA Mini Kit (Qiagen), in accordance with
the manufacturer’s instructions for large sample volumes. Part
of each RNA sample was used for cDNA synthesis immediately
after extraction, and the remainder was stored at 80C.
Construction of DNA and RNA standards for quantitative
real-time PCR for differential amplification of L90M and
M184V mutations. The primers for PCR and RT-PCR were
designed on the basis of published sequences within the pol
region of HIV-1HXB2. Oligonucleotides were synthesized by
Operon Technologies (Alameda, California). A plasmid encod-
ing HIV-1HXB2 (Aaron Diamond AIDS Research Repository) was
used as a background DNA template for the construction of
DNA and RNA transcripts. Regions within the pol gene of
HIV-1HXB2 were cloned into pGEM-T (Promega), in accordance
with the manufacturer’s instructions. The L90M (TTG to ATG
transversion in codon 90 of the protease gene) and M184V
(ATG to GTG transversion in codon 184 of the RT gene) drug-
resistance mutations were introduced into the pGEM-T HIV-
1HXB2 plasmid by site-directed mutagenesis, by use of a Quik-
Change Site-Directed Mutagenesis Kit (Stratagene) and the
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Table 1. Baseline characteristics of subjects before structured treatment interruptions (STIs).
Subject
Age,
years Sex
Route of
infection
Duration of HIV-1
infection, years
CD4 cell counts,
cells/mm3 HIV subtype
VL before HAART,
copies/mL
HAART received
before STIb
Time of VL
!50 copies/mL
before STI,
months
101 40 M Het 114 719 B 46,452a ddI, d4T, NFV 17
102 41 M MSM 17 723 B 561,831 AZT, 3TC, IDV 32
103 42 M Het 17 272 E/CRF1 26,568a ddI, d4T, NFV 12
104 47 M MSM 12 526 A 1,502,850 AZT, 3TC, NFV 26
105 52 F Het 3 1269 B 128,555a AZT, 3TC, IDV 26
106 39 M IVDA 19 878 B 506a AZT, 3TC 36
107 44 F Het 17 544 B 5216 AZT, 3TC, NFV 25
109 38 M MSM 19 1115 B 34,752 AZT, 3TC, RTV 31
111 38 M MSM 13 422 B 122,902a ddI, d4T, NFV 11
112 46 M IVDA 14 347 B 32,608a AZT, 3TC, IDV 25
113 59 M MSM 13 995 B 107,303 AZT, 3TC, RTV 20
114 32 M MSM 17 907 B 9275 AZT, 3TC, RTV 29
115 24 M MSM 12 570 B 54,693a d4T, 3TC, NFV 21
116 53 M Het 12 350 B 467,593 AZT, 3TC, IDV 32
117 33 F IVDA 4 489 B 29,345a AZT, 3TC, RTV 36
118 33 M MSM 4 832 B 16,927 AZT, 3TC, IDV 30
119 35 M Het 11 440 B 114,117a d4T, 3TC, SQV, RTV 12
120 55 M Het 12 766 B 162,701a AZT, 3TC, IDV 28
121 38 M Het 12 591 B 164,772 d4T, 3TC, NFV 12
122 40 M MSM 114 669 B 13,348a AZT, 3TC, IDV 30
123 39 F IVDA 18 1335 B 14,410 AZT, 3TC, RTV 25
124 43 M IVDA 12 715 B 19,453a ddI, d4T, NFV 19
125 35 F Het 15 777 E/CRF1 11,298 ddI, d4T, NFV 23
126 49 M MSM 17 842 B 63,698 AZT, 3TC, RTV 34
127 52 F Het 14 839 B 25,417 d4T, 3TC, NFV 22
128 43 F IVDA 12 749 B 9404 AZT, ddI, NFV 25
129 44 F Het 11 639 C 1,287,812 AZT, 3TC, IDV 29
130 66 M Het 1 670 A 821a AZT, 3TC, NFV 30
Median 42 4 717 33,680 26
Average 43 5 720 179,808 25
SD 9 4 261 368,727 7
NOTE. 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; ddI, didanosine; HAART, highly active antiretroviral therapy; Het, heterosexual; HIV, human im-
munodeficiency virus; IDV, indinavir; IVDA, intravenous drug abuse; MSM, men who have sex with men; NFV, nelfinavir; RTV, ritonavir; SQV, saquinavir; VL, virus
load.
a Mean pretreatment HIV-RNA values when 2 values before initiation of HAART were available.
b All subjects reached full suppression of plasma viremia (!50 copies/mL) after receiving these combination antiretroviral drug regimens and had never received
nonsuppressive mono- or double nucleoside reverse-transcriptase inhibitor therapy.
oligonucleotides tgL90M 5′-CTGTCAACATAATTGGAAGA-
AATCTGATGACTCAGATTGGTTGCAC-3′ (nt 2494–2539),
tgL90Mrc 5′-GTGCAACCAATCTGAGTCATCAGATTTCTTC-
CAATTATGTTGACAG-3′ (nt 2494–2539), tgM184V 5′-GACA-
TAGTTATCTATCAATACGTGGATGATTTGTATGTAGGATC-
TGAC-3′ (nt 3078–3125), and tgM184Vrc 5′-GTCAGATCCTAC-
ATACAAATCATCCACGTATTGATAGATAACTATGTC-3′ (nt
3078–3125), in accordance with the manufacturer’s instructions.
The introduction of each mutation into the pGEM-T HIV-1HXB2
template DNA was confirmed by sequencing.
DNA standards for quantification were prepared by PCR
from plasmid DNA constructed by in vitro mutagenesis. Wild-
type and mutant L90M-M184V plasmid DNA were amplified
by PCR, and the amplicons were purified from excess prim-
ers, dNTPs, and protein by use of a QIAquick PCR purification
Kit (QIAGEN). The PCR contained 1 PCR buffer (QIAGEN),
0.5 mmol/L dNTPs (Gibco BRL), 0.4 mmol/L each primer (pol
2259 5′-GTCACTCTTTGCCAACGACC-3′ [HXB2 2259–2279]
and pol 3287 5′-CAGCACTATAGGCTGTACTGTC-3′ [HXB2
3266–3287]) and 2.5 U of HotStarTaq DNA polymerase
(QIAGEN; final volume, 50 mL). The thermal-cycling condi-
tions consisted of 15 min at 95C, to activate the DNA poly-
merase, followed by 40 cycles (30 s at 94C, 30 s at 55C, and
1 min at 72C) and a termination of 5 min at 72C. The con-
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centrations of the purified wild-type and L90M-M184V am-
plicons (dsDNA, 1029 nt in length) were measured by UV-
absorbance spectrophotometry. Ten-fold serial dilutions of the
purified dsDNA transcripts with known molar concentrations
were used as templates to generate the standard curves used
for selective amplification by fluorescence-based real-time PCR.
RNA transcripts corresponding to the wild-type and L90M
and M184V drug-resistance mutations were prepared by in
vitro transcription of PCR products that contained the T7 RNA
polymerase promoter site, by use of the MEGAscript T7 kit
(Ambion). DNA templates for in vitro transcription were gen-
erated by PCR from wild-type and L90M-M184V plasmid
DNA. The PCR contained 1 PCR buffer, 0.5 mmol/L dNTPs,
0.4 mmol/L each primer (T7-pol 2258 5′-TAATACGACTCA-
CTATAGGGGTCACTCTTTGCCAACGACC-3 [nt 2258–2279;
T7 promoter sequence is underlined] and pol 3458 5′-TTAGA-
ATCTCTCTGTTTTCTGCC-3′ [HXB2 3458–3480]) and 2.5 U
of HotStarTaq DNA polymerase (final volume, 50 mL). The
thermal-cycling conditions consisted of 15 min at 95C, fol-
lowed by 40 cycles (30 s at 94C, 30 s at 55C, and 80 s at
72C) and a termination of 5 min at 72C. The concentrations
of the purified DNAse-treated RNA transcripts (1223 nt in
length) were measured by UV-absorbance spectrophotometry.
Selective quantification of wild-type and L90M and M184V
drug-resistant HIV-1 strains. Reverse transcription with viral
RNA from plasma samples was performed as described else-
where [21]. In brief, 20 mL of viral RNA and 0.5 mmol/L of a
gene-specific primer recognizing either the HIV-1 protease gene
(5′-GCCATCCATTCC-3′ [nt 2592–2603]) or the HIV-1 RT
gene (5′-GGTTCTTTCTGATG-3′ [nt 3210–3223]) were used.
Amplification of HIV-1 cDNA or genomic DNA was per-
formed by use of 2 external primer pairs in the same reaction:
1 primer pair for each region of interest (either wild type or
mutant), to optimize the primer binding sites. PCRs consisted
of 20 mL of cDNA, 1 PCR buffer II (Applied Biosystems),
3.5 mmol/L MgCl2, 0.5 mmol/L dNTPs (GibcoBRL), 0.4 mmol/
L each upstream primer (L90 EP1 5′-GAAGCTCTATTAGATA-
CAGG-3′ [nt 2313–2332] and M184 EP1 5′-AATCCAGACATA-
GTTATCTATC-3′ [nt 3072–3093]), 0.4 mmol/L each down-
stream primer (L90 EP2 5′-TTTAAAGTGCAACCAATCTGAG-
3′ [nt 2524–2545] and M184 EP2 5′-TTTTTTGTCTGGTGTG-
GTAAATC-3′ [nt 3187–3209]), and 2.5 U of AmpliTaq Gold
DNA polymerase (Applied Biosystems; final volume, 50 mL).
Amplification was performed for 15 cycles (15 s at 94C, 1 min
at 43C, and 30 s at 72C) in a Mastercycler gradient (Eppendorf
Scientific). PCR products were purified by use of a QIAquick
PCR purification kit (Qiagen), in accordance with the manu-
facturer’s instructions.
Nested real-time amplification of HIV-1 DNA was performed
separately for each region of interest (either wild type or mu-
tant), by use of 10 mL of first-round PCR product, 1 x-
rhodamine–PCR buffer, 3.5 mmol/L MgCl2, 0.5 mmol/L dNTPs
(GibcoBRL), 0.2 SYBR green (Molecular Probes), 0.4 mmol/
L each primer (pol 2316 5′-GCTCTATTAGATACAGGAGC
AG-3′ [nt 2316–2337] and IN L90 5′-TGCAACCAATCTGA-
GTCIA-3′ [nt 2520 -2538] or IN L90M 5′-TGCAACCAATCTG-
AGTCIT-3′ [nt 2520–2538]; and pol 3206 5′-TTTGTCTGGTGT
GGTAAATCCCCAC-3′ [nt 3182–3206] and IN M184 5′-CCA-
GACATAGTTATCTATCAATA IA-3′ [nt 3075–3099] or IN
M184V 5′-CCAGACATAGTTATCTATCAAT AIG-3′ [nt 3075–
3099]), and 2.5 U of AmpliTaq Gold DNA polymerase (Applied
Biosystems; final volume, 50 mL). Fifty cycles of amplification
(15 s at 94C, 30 s at 60C, and 30 s at 72C) were performed
in an Applied Biosystems 7700 Prism spectrofluorometric ther-
mal cycler (Applied Biosystems).
DNA standards were tested in duplicate for each experiment.
The standards were prepared by serial dilution from 106–10
copies/reaction. Viral RNA samples were also tested in dupli-
cate. Copy numbers were calculated by interpolation of the
experimentally determined threshold cycle for the test specimen
onto a control standard regression curve [25]. The ratio of
wild-type and mutant sequences was calculated on the basis of
copy numbers for each population. Nested real-time PCR assays
have a detection limit of 10 HIV-1 DNA copies/reaction, with
a linear dynamic range of 16 logs.
Since low virus loads diminish the discriminatory ability of
each assay, the final calculation of the percentage of minor
variants was dependent on the virus load. On the basis of the
protocol used in the present study, the equivalent of 11.2% of
the virus load (in RNA copies per milliliter) was estimated for
use in the first round of PCR and, subsequently, in the quan-
titative real-time PCR assays for differential amplification (virus
load in 1 mL of plasma  100%; 560 mL of plasma used for
RNA isolation 56%; two-fifths of eluted RNA used for cDNA
synthesis  22.4%, and half of cDNA used for first round of
PCR  11.2%). For each sample, the limit of detection of
minority variants was calculated on the basis of the virus load.
For instance, a virus load of 893 RNA copies/mL of plasma
results in 100 cDNA copies (11.2%) used in the first round of
amplification. Therefore, the equivalent of 100 cDNA copies is
used in quantitative real-time PCR for differential amplifica-
tion. Because of the detection limit of 10 DNA copies/reaction
in each real-time PCR, at least 10 copies of the initial 100 cDNA
copies have to carry the mutant to be detectable; this equals
10% in this example—anything !10% is not detectable. Thus,
an individual cut-off value was estimated for every sample.
Therefore, samples with virus loads of !500 HIV-1 RNA copies/
mL of plasma were not tested. The results of quantitative real-
time PCR assays were then compared with these calculations
and were adjusted such that detection of minor populations
was considered to be negative when the limit of detectable
minorities was higher on the basis of individual cut-off values.
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Figure 1. Scheme and discriminatory ability of quantitative real-time
polymerase chain reaction (PCR) for differential amplification. A, Wild-
type– or mutant-specific primers and a nonselective primer were used
to amplify the region of interest. Amplicons were quantified by real-time
PCR by use of SYBR green. B, Equal amounts of either wild-type () or
mutant () standard DNA templates were amplified with the wild-type–
specific (left panels) or mutation-specific (right panels) primers. The dis-
criminatory abilities (DCT) are indicated in the upper left corner, for each
assay. C, Discriminatory ability of real-time PCR for differential amplifi-
cation. Amplification of wild-type human immunodeficiency virus type 1
(HIV-1) DNA was performed by use of a serial dilution of standard wild-
type HIV-1 DNA either with () or without () the addition of 106 copies
of standard mutant HIV-1 DNA. Reactions were performed in duplicate,
and the mean values are shown. The solid lines indicate amplification
without the addition of mutant DNA (left panel). Amplification of mutant
HIV-1 DNA was performed by use of a serial dilution of standard mutant
HIV-1 DNA either with () or without () the addition of 106 copies of
standard wild-type HIV-1 DNA. The linear standard curve for amplification
of mutant DNA alone is shown in black (right panel). SDs are contained
within the data points. NT, without correct DNA template.
RESULTS
Differential amplification of HIV-1 variants by quantitative
real-time PCR. The quantitative real-time PCR assay used in
the present study is based on the amplification refractory mu-
tation system (ARMS) [26]. This assay uses allele-specific oli-
gonucleotides for detection of either wild-type or mutant se-
quences (figure 1A). To evaluate the discriminatory ability of
each assay, wild-type and mutant DNA standards were used for
amplification with the corresponding and the noncorresponding
oligonucleotides. Amplification of L90M DNA by the wild-type–
specific primer was detected by a positive fluorescent signal,
which appeared ∼14 PCR cycles after the signal for the wild-type
target. This is equivalent to a decreased efficiency of amplification
of 110,000-fold (figure 1B). The discriminatory ability (DCT) for
the amplification of both targets, with the mutation-specific
primer, is 16, which is equivalent to a 160,000-fold decrease in
efficiency of amplification of the incorrect target. Evaluating the
discriminatory ability of the M184/V assay resulted inDCT values
of 11 and 10 for M184 and M184V, respectively (data not shown).
In addition, the discriminatory ability of each assay was
tested in reciprocal mixing experiments by adding 106 copies
of noncomplementary DNA to a serial dilution (106–10 copies)
of either wild-type or mutant standard DNA. In each case, the
threshold cycle was compared to PCRs performed without the
addition of noncomplementary DNA. The discriminatory abil-
ity of this assay was comparable to that obtained from the
experiments described above (figure 1C). Taking into account
SD, the estimated discriminatory abilities for the different wild-
type and mutant sequences are as follows: 0.01% for detection
of L90 wild type as minority population, 0.01% for L90M, 0.1%
for M184, and 0.2% for M184V. The dynamic range of all assays
is 16 logs.
To overcome the problem of HIV-1 heterogeneity, multiplex
PCR with external primer pairs was performed before the sam-
ples were amplified by quantitative real-time PCR. Oligonu-
cleotides were chosen, covering almost the entire primer bind-
ing site used for selective amplification. Only a few PCR cycles
at low annealing temperatures were necessary to prepare viral
genomes from different subjects, for quantitative real-time
PCR. Standard DNA was tested by use of 1 or all external primer
pairs in the same reaction. No differences in threshold cycles
and discriminatory abilities were observed. Clones with differ-
ent known mutations in primer binding sites were first am-
plified with external primer pairs and then were used for nested
quantitative real-time PCR for differential amplification. Use
of sequences carrying 1 or 2 mutations in primer binding sites
did not result in any significant difference in threshold cycles
and discriminatory ability, compared with standard templates
that were completely homologous. When sequences contained
3 or 4 mutations in the primer binding site, a positive fluo-
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rescent signal appeared 14 cycles later. However, the discrim-
inatory ability was not affected (data not shown).
Quantification of minor populations of drug-resistant HIV-
1 in subjects undergoing STI. A total of 28 subjects under-
going STI were enrolled in this study. The baseline character-
istics of the study subjects are shown in table 1. All subjects
had chronic HIV-1 infection and were successfully treated with
HAART (virus load of !50 HIV-1 RNA copies/mL of plasma).
At least 1 protease inhibitor was included in the treatment
regimens of 27 subjects. All subjects were evaluated for HIV-
1 carrying the L90M and M184V mutations. Subjects 102, 103,
109, and 116 had to be retreated, according to the protocol,
between weeks 40 and 52. Subject 104 dropped out of the study
because his virus load measurements were 150 HIV-1 RNA
copies/mL of plasma after 10 weeks of retreatment. Analyses
of viral and immunological responses in these subjects have
been published elsewhere [14–16, 27].
The assay for detection of the L90M mutation was performed
on samples from 27 subjects. It was not possible to successfully
amplify wild-type or mutant sequences from 2 of these subjects
(129 and 130). These subjects were infected with HIV-1 sub-
types A and C, respectively. The L90M mutation was detected
as a minor variant in 3 of 25 subjects (subjects 102, 116, and
118) (table 2). In subject 102, 5.6% of the total HIV-1 popu-
lation carried the L90M mutation during the first cycle of STI
(figure 2). Interestingly, the L90M mutation was not detected
in this subject’s virus population during subsequent STI cycles.
In subject 116, 0.3% of the virus population carried the L90M
mutation during the third cycle of STI. Similarly, in subject
118, 0.06% of the virus population carried the L90M mutation
at 1 time point during the fifth cycle of STI. No evidence was
found for the presence of the L90M mutation in viruses from
any other study subjects.
All 28 subjects were tested for the presence of the M184V
mutation. We were unable to amplify either wild-type or
M184V mutant sequences in samples from 3 subjects (103, 129,
and 130). These subjects were infected with HIV-1 subtypes
different from subtype B (table 1). Overall, drug-resistant HIV-
1 variants carrying the M184V mutation were detected in 14
of 25 subjects. In 9 subjects, minority virus populations carrying
the M184V mutation were detected at only 1 or 2 time points.
In 7 subjects, this mutation was detected once, as a minority,
during the fifth cycle of STI (see “subject 106” in figure 2 and
table 2), with percentages ranging from 0.3% to 9.8% (average,
3.1%). The M184V mutation was not detected in subsequent
samples from these subjects. Among viral sequences identified
for subject 127, 5.4% carried the M184V mutation during the
second STI cycle, but not during subsequent STI cycles. In
subject 106, the M184V mutation represented 56.9% of the
sequences detected during the beginning of the fifth STI cycle.
This population decreased to 1% 2 weeks later and decreased
to !0.3% after an additional 2 weeks. Lower virus loads in
subsequent samples did not allow us to discriminate between
wild-type and mutant variants below the range of 2.6%–6.6%.
Because of low virus loads during the first 4 STI cycles, only
time points from the fifth STI cycle were measured. However,
calculating the positive values of the M184V mutation relative
to the virus load revealed that 56.9% corresponded to ∼782
HIV-1 RNA copies/mL of plasma. Because of a rapid increase
in virus load in this subject (106), 1% corresponds to ∼451
HIV-1 RNA copies/mL of plasma. This indicates that the wild-
type population was increasing during this period, whereas the
M184V mutant population was slowly decreasing.
Five subjects showed diverse patterns, with regard to the
appearance of the M184V mutation (figure 2 and table 2).
Analysis of samples from subject 102 revealed a continuous
decrease in viruses carrying the M184V mutation, during the
first 3 cycles of STI (20.1%, 5.2%, and 4.9%, respectively). The
M184V mutation was not detected within the range of de-
tectable minor variants during subsequent STI cycles. This sub-
ject resumed ART (zidovudine, lamivudine, and indinavir) on
day 329. The majority of viruses identified for subject 104
carried the M184V mutation at baseline, with 93.9% detected
by day 8 of the first STI cycle. After reintroduction of HAART,
the virus load decreased; however, the M184V mutation was
detectable at levels of ∼60%–80%, up to day 70. This subject
subsequently dropped out of the STI study because his virus
load did not decrease to !50 HIV-1 RNA copies/mL of plasma
after the first STI cycle. Viremia continued to decrease but
remained detectable at low levels (!500 HIV-1 RNA copies/
mL of plasma). Five months later, virus load rebounded to
11000 HIV-1 RNA copies/mL of plasma. Population sequenc-
ing revealed the M184V mutation and the protease inhibitor–
associated mutations 46L, 54V, 63P, and 82A. A salvage regimen
was started with abacavir, saquinavir, ritonavir (changed to
lopinavir/ritonavir after 20 months), and stavudine. Efavirenz
was added to the regimen after 1 month. Virus load decreased
and remained undetectable in plasma for the duration of
follow-up (figure 2).
Viral variants carrying the M184V mutation were detectable
as a minority population in samples obtained from subject 105
during the fifth STI cycle. The percentage of M184V mutants
varied between 0.5% and 11% during this time but did not
disappear, despite the fact that the subject was not receiving
ART. Time points before the fifth STI cycle were not analyzed,
because of low virus load. The first sample from subject 112
that was measured was obtained during the third STI cycle;
samples of earlier STI cycles have not been used for differential
amplification, because of low virus loads. Approximately 50%
of the virus population from subject 112 carried the M184V
mutation during the third STI cycle. During the fourth STI
cycle, the M184V mutation was not detectable (!2.1%), but it
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Figure 2. Kinetics of virus load and detection of drug-resistant viral sequences in subjects undergoing structured treatment interruption (STI).
Human immunodeficiency virus type 1 (HIV-1) RNA in plasma was measured by use of an Amplicor HIV-1 Monitor test (version 1.5; Roche Diagnostics)
(). Drug-resistant variants carrying either the L90M or M184V mutations were detected by quantitative real-time polymerase chain reaction for
differential amplification. The percentage of the virus population carrying the specific mutation was used to calculate the absolute HIV-1 RNA copies
per milliliter of plasma, on the basis of the corresponding virus load measurement. Copy numbers representing the L90M variants () and M184V
variants () are shown. Numbers represent percentages of each drug-resistant virus population. Percentage values below the limit of detectable
minorities, because of low virus load, are printed in italic type. The limit of sensitivity (90 copies of HIV-1 RNA) is indicated by the dotted line. The
shaded areas represent periods of STI comprising 4 cycles; each cycle comprised 2 weeks without HAART followed by 8 weeks of resumed treatment.
Treatment was discontinued for at least 3 months, at week 40, and was resumed if necessary. Subject 104 dropped out of the study because his
virus load did not decrease to !50 HIV-1 RNA copies/mL of plasma after the first STI cycle.
STI and Minorities of Drug-Resistant Viruses • JID 2003:188 (15 November) • 1441
appeared again during the fifth STI cycle, showing an increase
over time. In subject 116, the M184V mutation was detectable
as a minor variant during the first STI cycle (0.9%), the second
STI cycle (0.3%), and the third STI cycle, at days 148 (5.9%)
and 154 (0.8%). During the fourth STI cycle, the level of viruses
carrying the M184V mutation reached 27.3%. HAART was
reintroduced in this subject 33 days after the fifth STI.
All subjects had received their first ART before they were
enrolled in SSITT. To determine whether minor populations
carrying the L90M and M184V mutations were already present,
before initiation of HAART, in our subjects’ virus populations,
we also tested plasma samples obtained from 24 of these sub-
jects when they were still drug naive—that is, before any ART
was started. No successful amplification of wild-type or mutant
sequences was possible in samples from 3 (L90/M) and 2
(M184/V) subjects, respectively. In the remaining samples, no
minor variants of viruses carrying the L90M or M184V mu-
tations were detectable. With regard to the L90M mutation,
frequencies were !0.03%–!1% (median, !0.2%) in samples
from 21 subjects. The M184V mutation was not detectable in
22 subjects, at frequencies of !0.2%–9.1% (median, !0.5%).
DISCUSSION
The present study was undertaken to analyze the potential
emergence of drug-resistant HIV-1 in subjects undergoing STI.
Genotypic analysis of minor populations was performed by use
of a novel, quantitative real-time PCR assay for differential
amplification with selective oligonucleotides that detect 2 key
resistance mutations: L90M (protease) and M184V (RT). This
methodology is based on the ARMS [26]. Gene-specific oli-
gonucleotides contained a deoxyinosine at the 2 position of
the 3′ end that, because of destabilizing effects on the formation
of duplexes, increased the discriminatory ability 5–10-fold (data
not shown). In addition, since deoxyinosine is less tolerant of
mismatches, variability in the second position, among different
viral sequences, is less critical [28]. This methodology is able
to detect a low percentage of minor populations of L90 wild-
type and L90M drug-resistant variants (0.01%), as well as M184
wild-type (0.1%) and M184V drug-resistant variants (0.2%).
A total of 28 subjects were enrolled in the present study; 181
plasma samples from 25 subjects were analyzed for the presence
of the L90M mutation. This mutation was detected as a minor
population in 3 samples from 3 of 25 subjects. A total of 216
plasma samples from 25 subjects were analyzed for the presence
of the M184V mutation: 40 samples from 14 subjects were
positive for the M184V mutation. The predominance of the
M184V mutation, compared with the L90M mutation, was not
unexpected. The selection of mutations associated with drug
resistance to protease inhibitors is a slow, stepwise process [29,
30], compared with the emergence of M184V, which is a single-
point mutation selected by lamivudine [31]. Thus, the more
frequent detection of the M184V mutation, compared with the
L90M mutation, might represent a very early event in the emer-
gence of drug resistance in our subjects undergoing several
periods of significant HIV-1 replication [26].
The majority of subjects in this study were infected with
HIV-1 subtype B (table 1), and samples from each of these
subjects have been successfully amplified. Five subjects were
infected with other HIV-1 subtypes. Although HIV-1 clones
containing mutations at different positions in the primer bind-
ing sites were successfully amplified in the set up of validation
of this method, only HIV-1 from 2 of these subjects was am-
plified by use of both L90M and M184V real-time PCR; how-
ever, it was not possible to amplify samples from 2 other sub-
jects (129 and 130). Samples from subject 103 were successfully
analyzed, with respect to the L90M mutation, but we were
unable to generate amplicons to detect the M184V mutation.
It is likely that the oligonucleotides did not hybridize to the
HIV-1 targets of the subjects, because of too many mutations
in the primer binding site. The use of external primer pairs in
combination with low annealing temperatures during the first
PCR reaction and a deoxyinosine at the 2 position of the 3′
end of the selective oligonucleotides are efforts to minimize the
influence of differences in viral sequences. This procedure is
successful, with respect to HIV-1 subtype B. However, a small
risk of underestimating 1 or the other HIV-1 variant cannot
completely be denied.
Sporadic occurrence of the L90M mutation was detected in
3 subjects during STI. This mutation appeared only once in
each subject, during different STI cycles. The percentage of
viruses carrying the L90M mutation was !0.3% in subjects 116
and 118. We cannot rule out the possibility that a minor pop-
ulation of L90M variants within this range may be present at
other time points; however, for most of the other samples, low
virus loads did not allow us to discriminate !1%. In 9 subjects,
the M184V mutation was detected during the fifth STI cycle in
only 1 or 2 samples. It is possible that M184V was also selected
during prior STI cycles, but, because of lower virus loads during
these periods, the M184V mutation was not detectable. On the
other hand, more samples were suitable for testing during the
last (fifth) STI cycle, increasing the probability of detecting mu-
tations, because of the occurrence of a full rebound in virus load,
compared with the shorter, prior STI cycles. Interestingly, 2 of
these subjects were treatment naive with respect to lamivudine.
Instead, their regimen contained didanosine. That virus strains
harboring the M184V mutation show reduced sensitivity against
didanosine in vitro may potentially lead to selection of minor
populations carrying the M184V mutation in subjects receiving
didanosine treatment [32].
Baseline samples (from the first STI cycle, if available) from
3 subjects were positive for the M184V mutation. This mutation
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was not detected in subsequent samples obtained from subject
102 during successive STI cycles. In subject 116, the frequency
of variants carrying M184V increased in subsequent STI cycles.
Drug-specific pharmacokinetic factors were excluded as an ex-
planation for the divergent outcomes, because subjects 102 and
116 each received the same drugs. However, we cannot rule
out the possibility that other pharmacokinetic factors, such as
differences in drug absorption, led to concentrations that fa-
vored the outgrowth of the M184V mutation in this subject.
Of the 25 subjects studied, only subject 104 developed drug-
resistance mutations associated with treatment failure. On day
8 of the first STI cycle, the majority (193%) of viruses from
this subject already harbored the M184V mutation (figure 2).
This finding was confirmed by direct sequencing (L. Perrin,
personal communication). The M184V mutation was found,
in addition to multiple mutations associated with resistance to
protease inhibitors. The subject dropped out of the study with
a virus load of 150 HIV-1 RNA copies/mL of plasma after the
first STI cycle. A salvage regimen was subsequently introduced
with successful suppression of plasma viremia to !50 HIV-1
RNA copies/mL for 127 months.
In subject 105, minor populations carrying the M184V mu-
tation were detected at frequencies of 0.5%–11% throughout
the fifth STI cycle. No consistent pattern of change was ob-
served, suggesting that other mutations, in addition to M184V,
may influence the replication of minor variants in this subject
and in others (e.g., subject 112). During the third STI cycle,
approximately half of the virus population contained the
M184V mutation. This mutation decreased during the fourth
and fifth STI cycles, to percentages between !1.4% and 9.4%,
and increased again, to 46.4%, between weeks 9 and 10 of the
fifth STI cycle. Fluctuations in the frequency of the M184V
mutation have been observed in some subjects. The appearance
of different quasi species at different time points might reflect
the heterogeneity of HIV-1. Changes in the ratio between wild-
type and mutant virus populations may be related to different
advantages, such as viral fitness, for certain virus populations
at different stages.
There is one potential caveat to our study: the very high
sensitivity of our assay to detect the 2 mutations at very low
frequencies, in theory, may have lead to detection of randomly
occurring minor populations present in subjects with chronic
infection, independent of treatment and, in particular, STI.
However, that the rapidly emerging single-point mutation
M184V was detected in 14 of 25 subjects, compared with only
3 of 25 subjects harboring the slow-emerging L90M mutation
( , Fisher’s exact test), suggests that our results are caus-Pp .02
ally linked to treatment and STI. The finding of a higher fre-
quency of the M184V mutation, compared with the L90M
mutation, is even more prominent if one considers the 20-
times higher sensitivity of the L90M assay. Furthermore, both
mutations have not been detected in plasma samples obtained
from these subjects at time points before they received their
first ART.
In conclusion, drug-resistant viruses were detected as minor
populations of HIV-1 in the majority of subjects undergoing
STI. It is not yet known whether a similar distribution occurs
in subjects who stop successful therapy for longer periods with-
out consistent reintroduction of HAART. However, our data
suggest that such variants can emerge during periods of in-
creased HIV-1 replication, when drug concentrations may be
suboptimal. We observed tremendous variation in the appear-
ance and disappearance, as well as in the timing of the emer-
gence, of these mutations. On the basis of these observations,
we suggest that STI should remain restricted to controlled clin-
ical trials, to minimize the risk of the development of drug-
resistant HIV-1 variants. The influence of minor populations
of drug-resistant variants on long-term treatment is currently
under investigation.
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